ADCs are a class of biopharmaceutical drugs that deliver cancer-killing agents directly to cancer cells – a far more targeted approach than conventional chemotherapy. Optimizing ADCs requires analytical technologies to comprehensively characterize the molecule, including its biochemical attributes like drug-to-antibody ratio (DAR) and sites of conjugation.
As biopharmaceutical organizations continue to explore the use of ADCs as a class of cancer therapies, they find significant challenges with analyzing their complex, heterogenous structures. However, a well-characterized ADC is critical to advance from discovery through clinical development and to commercialization.
Successfully address your characterization challenges with exceptional insight into your molecules from Waters fit-for-purpose ultra-performance liquid chromatography (UPLC), high resolution mass spectrometry (MS), column chemistries, and informatics solutions. Trust Waters to help simplify complex molecule analysis and accelerate your ADC characterization and monitoring of critical quality attributes.
Case Study: How Waters is Helping to Support the Development of Novel Therapies